Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

AVAILABLE

Study Classification

EXPANDED_ACCESS

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this Expanded Access Program (EAP) is to provide access to sevabertinib, for participants previously treated with locally advanced or metastatic non-small cell lung cancer (NSCLC) with mutations in the human epidermal growth factor receptor 2 (HER2) gene, which have no other therapeutic option.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Non-small Cell Lung Cancer Cancer

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sevabertinib

Sevabertinib is self-administered by the patient BID (twice a day) as tablets for oral administration

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

BAY2927088

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Signed and dated written informed consent
* Age ≥18 years
* Histologically or cytologically confirmed locally advanced or metastatic NSCLC
* Documented disease progression after treatment with at least one prior systemic therapy for advanced disease
* Documented HER2 activating mutation
* Expected minimum life expectancy of 12 weeks
* Performance status of 0 or 1
* Participants must be able to take oral medication
* Blood test results within certain ranges
* Adequate coagulation as assessed by lab tests or on stable anticoagulation treatment
* Adequate cardiac function
* Negative serum pregnancy test in women of childbearing potential within 72 hours of the first dose
* Ability to receive prescription of loperamide from the treating physician

Exclusion Criteria

* Investigational agent or anticancer therapy within 2 weeks prior to planned start of sevabertinib or 5 half-lives, whichever is shorter, and without recovery of clinically significant toxicities from that therapy
* Prior progression while receiving approved or investigational tyrosine kinase inhibitors targeting HER2
* Symptomatic or unstable brain metastases
* Treatment with immunotherapy ≤ 28 days prior to the first dose of IMP
* Past medical history of Grade ≥2 ILD, drug-induced interstitial lung disease
* Inability to discontinue treatment with a strong CYP3A4 inhibitor or inducer prior to start of treatment initiation
* Any uncontrolled intercurrent illness or condition including, but not limited to, uncompensated respiratory, cardiac, hepatic, or renal disease, ongoing or active infection (including active clinical tuberculosis), renal transplant or psychiatric illness/social situations that would limit compliance
* Pregnancy or lactation
* History of clinically significant cardiac disease

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Bayer Clinical Trials Contact

Role: CONTACT

Phone: (+)1-888-84 22937

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

22913

Identifier Type: -

Identifier Source: org_study_id

22978

Identifier Type: OTHER

Identifier Source: secondary_id